Series A Round

Leyden Labs helps people live freely by developing products that protect from known and new respiratory viruses. The company focuses on creating non-vaccine intranasal antibody programs to safeguard individuals from respiratory viruses. This funding round will support the advancement of their innovative intranasal antibody programs aimed at providing protection against a wide range of respiratory viruses.